MedWatch

Bank analyst on Novo Nordisk report: Impressive quarter, to say the least

Novo Nordisk has beaten expectations in terms of both its GLP drugs and its obesity treatment, and according to senior equity analyst at Sydbank Søren Løntoft Hansen, the report which Denmark's largest pharmaceutical company sent out Wednesday afternoon is highly impressive.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The Q2 report that Novo Nordisk introduced on Wednesday afternoon is impressive, to say the least.

This is according to Søren Løntoft Hansen, who is senior equity analyst at the Danish bank Sydbank.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs